Home › NDC Lookup › RxCUI directory › RxCUI 2123145

Erdafitinib 5 MG Oral Tablet [Balversa] — RxCUI 2123145

RxNorm drug concept · Semantic branded drug
RxCUI 2123145 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2123145
Official nameErdafitinib 5 MG Oral Tablet [Balversa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asBalversa 5 MG Oral Tablet
FDA products mapped3
Package NDCs mapped5
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Erdafitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats adults with advanced bladder or urinary tract cancer (urothelial carcinoma) that has a certain FGFR3 gene change. It's used after at least one earlier treatment has stopp...
  • Swallow the tablets whole once a day, with or without food. If you vomit, wait until the next day for your next dose. If you miss one, take it later that same day, then go back to...
  • Common ones include nail changes, mouth sores, diarrhea, dry mouth, dry skin, dry eyes, tiredness, appetite loss and taste changes. Many people need dose adjustments, so tell your...
  • Balversa can cause a retina problem called central serous retinopathy, which may affect your vision. You'll have exams monthly for the first four months and then every three months...
📖 Read our full Erdafitinib guide →

🕸️ Concept Web — How Erdafitinib 5 MG Oral Tablet [Balversa] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Erdafitinib 5 MG Oral Tablet [Balversa] RxCUI 2123145

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Erdafitinib 2123125
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Balversa 2123132
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Erdafitinib Oral Tablet 2123130
    • Erdafitinib Oral Product 2123128
    • Erdafitinib Pill 2123129
    • Erdafitinib Oral Tablet [Balversa] 2123134
    • Balversa Oral Product 2123135
    • Balversa Pill 2123136
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Erdafitinib 5 MG Oral Tablet SCD · 2123143
  • Erdafitinib 5 MG SCDC · 2123142
  • Erdafitinib Oral Tablet SCDF · 2123130
  • Erdafitinib Oral Product SCDG · 2123128
  • Erdafitinib Pill SCDG · 2123129

Brand-Name Concepts

  • Erdafitinib 5 MG [Balversa] SBDC · 2123144
  • Erdafitinib Oral Tablet [Balversa] SBDF · 2123134
  • Balversa Oral Product SBDG · 2123135
  • Balversa Pill SBDG · 2123136
  • Balversa BN · 2123132

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 2123145 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59676-0030-56 1 BOTTLE in 1 CARTON (59676-030-56) / 56 TABLET, FILM COATE... BALVERSA Janssen Products LP 2019-04-12
59676-0030-84 1 BOTTLE in 1 CARTON (59676-030-84) / 84 TABLET, FILM COATE... BALVERSA Janssen Products LP 2019-04-12
59676-0040-28 1 BOTTLE in 1 CARTON (59676-040-28) / 28 TABLET, FILM COATE... BALVERSA Janssen Products LP 2019-04-12
59676-0040-56 1 BOTTLE in 1 CARTON (59676-040-56) / 56 TABLET, FILM COATE... BALVERSA Janssen Products LP 2019-04-12
59676-0050-28 1 BOTTLE in 1 CARTON (59676-050-28) / 28 TABLET, FILM COATE... BALVERSA Janssen Products LP 2019-04-12
Observed labelers: Janssen Products LP (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.